QPPV.COM KNOWLEDGE ASSESSMENT

Tick-Borne Encephalitis Vaccine: Inactivated-Virus Biology, Immunisation and Pharmacovigilance

Test your understanding of the concepts covered by Tick-Borne Encephalitis Vaccine: Inactivated-Virus Biology, Immunisation and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which characteristic most directly explains why the vaccine cannot cause a replicating TBE infection?

It contains aluminium hydroxide as an adjuvant The whole virus has been inactivated with formaldehyde It is administered in a prefilled syringe It induces neutralising antibodies

Question 2 of 10 Which statement best describes the role of booster history in breakthrough-disease assessment?

Booster history is unnecessary once the first dose is documented Time since the most recent booster helps interpret whether protection might have waned relative to exposure A booster history determines whether the vaccine contains live virus Only the lot number of the booster is relevant

Question 3 of 10 Which statement best distinguishes a neurological adverse event from suspected lack of vaccine effectiveness?

They are identical because both occur after vaccination A neurological event concerns an illness temporally associated with vaccination, whereas lack of effectiveness requires evaluation for infection despite appropriate vaccination Lack of effectiveness is assessed only by recording local reactions A neurological event can be considered vaccine failure without confirming TBE infection

Question 4 of 10 What is the most appropriate interpretation of immunosuppression in relation to this vaccine?

It necessarily creates a distinctive adverse-event syndrome It may reduce the immune response, making suspected lack of effect a separate question from adverse reaction It guarantees vaccine-induced TBE infection It removes the need to document dose history

Question 5 of 10 A child receives the adult TBE vaccine presentation by mistake. Which is the best initial pharmacovigilance interpretation?

It is automatically a serious adverse reaction It is irrelevant if no symptoms occur It is a vaccination error requiring documentation of the intended and administered presentations It proves that the child has inadequate immunity

Question 6 of 10 A report states only 'encephalitis after TBE vaccine.' What is the most appropriate next step?

Classify it immediately as vaccine-caused encephalitis Assume it represents vaccine failure Reconstruct the clinical diagnosis, laboratory evidence, vaccination history and exposure context Close the case because inactivated vaccines cannot cause any neurological event

Question 7 of 10 A cluster of suspected vaccine failures is identified, but storage-excursion information is missing. What potential contribution may be overlooked?

The patient's unrelated allergy history A product-quality or cold-chain contribution to reduced vaccine performance The distinction between adult and paediatric presentations Whether the virus was inactivated with formaldehyde

Question 8 of 10 Which combination represents the most complete record for a suspected administration error?

Reporter name and general statement that a vaccine error occurred Intended presentation, actual presentation, administered volume, dose timing and corrective action Only the patient's age and whether fever developed Only the vaccine lot number

Question 9 of 10 Why should a vaccination history not be reduced to the single status 'vaccinated' in a pharmacovigilance database?

Because vaccination status has no relevance to safety assessment Because the number, timing and intervals of doses affect assessment of protection and use errors Because only the date of the first dose matters Because booster doses are unrelated to exposure risk

Question 10 of 10 A prefilled syringe is found to have a suspected defect, but no patient experienced an adverse event. Which governance interpretation is most appropriate?

The issue is irrelevant to pharmacovigilance because no adverse event occurred It may be relevant to quality and safety surveillance and should be routed through the appropriate governance processes It should be classified as confirmed breakthrough TBE It should be recorded only as a travel-related event

Tick-Borne Encephalitis Vaccine: Inactivated-Virus Biology, Immunisation and Pharmacovigilance

Cookie Settings